Caplin Point Laboratories has delivered exceptional financial performance in the third quarter, with revenue, EBITDA and net profit showing strong year-on-year growth. The pharmaceutical company's latest results demonstrate robust operational efficiency and continued momentum across key financial metrics.

Revenue Performance Shows Steady Growth

The company reported revenue of ₹5.4 billion in the third quarter, compared to ₹5.0 billion in the same period last year, representing a solid 8% year-on-year growth. This revenue expansion reflects the company's ability to maintain market momentum and drive business growth across its pharmaceutical operations.

Strong EBITDA Performance

The company reported impressive EBITDA growth with earnings reaching ₹1.9 billion in the third quarter, compared to ₹1.6 billion in the same period last year. This represents substantial operational improvement, reflecting enhanced business efficiency and effective cost management strategies.

The EBITDA margin also showed significant improvement, expanding to 35% from 32.9% in the previous year's corresponding quarter. This margin expansion indicates the company's ability to optimize operational costs while maintaining revenue growth momentum.

Net Profit Growth Continues

Caplin Point Laboratories reported consolidated net profit of ₹1.64 billion for the third quarter, marking a notable 17.14% increase compared to ₹1.40 billion recorded in the same quarter of the previous fiscal year. This consistent profitability growth demonstrates the company's strengthening financial position.

Operational Excellence

The combination of steady revenue growth, improved EBITDA margins and strong net profit growth reflects the pharmaceutical company's operational excellence and strategic execution. The enhanced margins indicate effective cost optimization while the absolute growth across revenue, EBITDA and net profit showcases the company's ability to scale operations efficiently.

These comprehensive financial metrics position Caplin Point Laboratories favorably within the competitive pharmaceutical landscape, demonstrating sustainable business practices and effective management strategies that have contributed to enhanced performance during the quarter.

Caplin Point Laboratories Limited has disclosed comprehensive voting results and scrutinizer report for the postal ballot concluded on January 31, 2026, revealing overwhelming shareholder support for the appointment of four new directors. The pharmaceutical company informed stock exchanges about the detailed voting outcomes under Regulation 44 of SEBI Listing Regulations.

Postal Ballot Process and Timeline

The postal ballot process was conducted entirely through remote e-voting, with the voting period commencing on January 2, 2026 at 9:00 AM and concluding on January 31, 2026 at 5:00 PM. The company dispatched the postal ballot notice dated December 29, 2025 via email to shareholders on December 31, 2025, with the cut-off date for voting eligibility set as December 26, 2025.

Voting Results Summary

All four resolutions received substantial shareholder approval, with voting participation reaching 78.35% of outstanding shares. The scrutinizer M. Alagar of Alagar & Associates LLP confirmed that all resolutions passed with requisite majority.

Detailed Voting Breakdown

The voting results demonstrated strong support across all shareholder categories. Promoter and Promoter Group, holding 53,642,353 shares, voted unanimously in favor of all resolutions with 100% participation. Public institutional investors, with 6,684,623 shares, showed 87.35% participation, while public non-institutional shareholders had 0.48% participation from their 15,684,720 shares.

New Board Appointments

The approved appointments include strategic leadership additions and enhanced independent oversight:

Professional Credentials

Mrs. Susan Mathew brings distinguished administrative expertise as a retired Indian Administrative Service officer with 36 years of government service. Her career included senior roles as Collector of Madras, Secretary to Government Energy Department, Chairman of Tamil Nadu Electricity Board, and Additional Chief Secretary. She holds academic credentials from Women's Christian College Chennai and was awarded the Lester Pearson Fellowship for studies at Carleton University and University of Ottawa.

Regulatory Compliance and Documentation

The company ensured full regulatory compliance with advertisements published in Financial Express (English) and Maalai Malar (Tamil) on January 1, 2026. The scrutinizer confirmed that all new directors meet regulatory requirements and are not debarred by SEBI or other authorities. Electronic voting data and records will be maintained in safe custody until the Chairman approves and signs the postal ballot minutes.